DiagnoCure Inc. reported consolidated earnings results for the first quarter ended January 31, 2014. For the quarter, the company's total revenues were $146,969 compared with $167,916 for the same period of 2013. This decrease of $20,947 or 12% is attributable to Hologic Gen-Probe PCA3 royalties.

Royalty revenues from Hologic Gen-Probe were $146,969, compared to $167,916 for the same period of 2013. This decrease is attributable to a decrease of 28% in U.S. royalty revenues and 4% in European royalty revenues as compared to the same period in 2013. Net loss (before stock-based compensation, depreciation and amortization) was $427,273 against $530,200 a year ago.

Net loss and comprehensive loss was $529,739 against $788,237 a year ago. Basic and diluted net loss per share was $0.01 against $0.02 a year ago.